Asthma and atopy are complex phenotypes that are influenced by both genetic and environmental factors. A review of nearly 500 papers on disease association studies identified 25 genes that have been associated with an asthma or atopy phenotype in six or more populations. An additional 54 genes have been associated in 2-5 populations. Here, we discuss the methods that have been used to identify susceptibility genes for common diseases and overview the status of asthma genetic research. Finally, current challenges and future directions are discussed.
Introduction
This year marks the tenth anniversary of the completion of the first genome-wide screen for asthma and atopy susceptibility loci 1 and a decade of intensive investigations in laboratories around the world to unravel the genetic basis of these complex phenotypes. At that time, family-based linkage studies followed by positional cloning held great promise for studying common, complex diseases because of the many successes of these approaches in identifying the genes that caused monogenic, Mendelian disorders and of the (then) recent initiation of the Human Genome Project. [2] [3] [4] [5] Although the road to asthma gene discovery has been bumpy, the ride has been well worth the trip. We enter into the second decade of investigation with six novel genes having been identified by positional cloning [6] [7] [8] [9] [10] [11] and over 100 genes by candidate gene association studies. Among the latter group of genes, 79 have been associated with an asthmaor atopy-related phenotype in two or more independent study samples ( Figure 1) .
In this review, we will overview these discoveries and provide some perspective on the current status of the field of asthma genetics in 2006. Reviews of studies of gene-gene and gene-environment interactions in asthma or atopy susceptibility have been reviewed elsewhere [12] [13] [14] [15] [16] and will not be specifically discussed here. Similarly, we will not review the results of genome-wide linkage studies or discuss in detail the six asthma and atopy genes that have been identified by positional cloning, but refer readers to other recent reviews on these topics. [17] [18] [19] [20] [21] [22] [23] [24] Candidate gene (association) vs genome-wide linkage studies
The advantages and disadvantages of these two approaches to gene discovery have been extensively discussed over the years and we will just highlight some of these issues from a 2006 perspective. The main advantage of linkage studies has been the promise of identifying both novel genes or pathways and genes with larger phenotypic effects. The latter point stems from the belief that only genes with large effects will generate a linkage signal in samples sizes that are typically used for genetic studies. This was thought to be particularly true if linkage to the same region was identified in multiple populations. However, it is becoming apparent that many, and perhaps most, of the regions that show linkage to asthma or a related phenotype in multiple populations harbor more than one susceptibility locus. The most obvious examples of this are the well replicated asthma or atopy linkages to chromosomes 5q31-33, 6p21, and 12q13-q24. 18, 25 At least 14 genes in the 5q region have been associated with an asthma or atopy phenotype, including some of the most replicated genes (IL4, IL13, CD14, ADRB2, SPINK5, LTC4S) ( Figure 1 ; Table S1 ), a positionally cloned gene (CYFIP2), 9 genes that show strong interactions with environmental exposures (CD14, TIM1) [26] [27] [28] and a gene that influences drug response (ADRB2). 29 The linked region on chromosome 6p21 at the HLA region includes both classical and nonclassical HLA genes and the genes encoding TNF, LTA, and TAP, many of which have been associated with asthma phenotypes in diverse populations ( Figure 1 ; Table S1 ). The broad linkage region on 12q spans from the VDR gene at the proximal end to the NOS1 gene at the distal end and includes the IFNG gene, all three of which have been associated with asthma or atopy in multiple samples (Table S1 ). In fact, one study suggested that different asthma-related phenotypes map to different locations within this broad linkage region. 30 Moreover, it is even likely that additional susceptibility loci reside within the same linkage peak and close to some of the positionally cloned genes, such as ADAM33 on chromosome 20p, 10 CYFIP2 on chromosome 5q, 9 and HLA-G on chromosome 6p21. 8 Therefore, it should not be assumed that linkage signals, particularly those that are wellreplicated, harbor genes with large effects. Rather, we propose that such regions more likely harbor multiple susceptibility loci, each with relatively small effects on disease risk. Thus, the sole advantage to genome-wide linkage studies in our opinion is the promise of identifying novel genes and pathways. However, with the recent ability to conduct genome-wide association studies, the possibility of identifying previously unsuspected candidate genes is no longer an attribute that is unique to linkage studies. 31 The main advantage of association studies is that this approach will detect genes with smaller effects in sample sizes comparable to those used in linkage studies. 32 In addition, recruiting unrelated cases and controls is easier and less expensive than recruiting families, and there is increased power in studying the equivalent number of individuals in a case-control association study than in family-based studies. For example, a study of 500 trios requires genotyping 1500 individuals and inevitably raises issues related to missing parental (usually paternal) data. For the equivalent costs, one could genotype 750 cases and 750 controls, which is an overall more powerful design. 32 Historically, the major criticism of case-control studies has been that unknown population substructure could result in differences in allele frequencies between the cases and controls that are unrelated to their disease status, resulting in an inflated type I error rate. Although association methods that use family-based controls were developed to avoid issues of population substructure, 33 there are now statistical methods available that allow for the detection of and correction for any imbalances between cases and controls, should they exist. 34, 35 Therefore, the advantages of family-based association studies compared with a case-control design may not outweigh the power advantage associated with the latter, as discussed above. IL1RN  IL1A  IL1B  DPP10  CCR5  IL5RA  TLR6  TLR10  TLR2  CSF2  IL5  IL12B  TIM1  TM3  HLA-G  HLA-DQA1  HLA-DPB1  TAP1  PAFAH  EDN1  IFNGR1  CCL24  CCL26  CFTR  NOS3   NAT2  DEFB1  TLR4  C5  GATA3  ALOX5  CRTH2  IL18  AICDA  VDR  IFNG  PHF11  CYSLTR2  TCRA/D  CMA1  PTGDR  CARD15  NOS2A  CRHR1  CCL11  TBX21  STAT3  ITGB3  ACE  C3  GSTT1  MIF COX2 (1) AGT (1) HMNT (3) STAT4 (1) CCR3 (2) TLR9 (3) IL8 (1) 
IL4RA ADAM33 Figure 1 Genes associated with asthma or atopy phenotypes in at least one published study (see Table S1 for descriptions of each of the studies). Genes are ordered according to their location on the chromosomes. Genes that have been associated in only one population are separated into those without any replication studies reported in the literature and those with subsequent studies that did not replicate the association (numbers in parentheses denote the number of subsequent studies). Genes identified by positional cloning studies are underlined.
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This past year has witnessed the first reports of genome-wide single nucleotide polymorphism (SNP) association studies of complex diseases using casecontrol designs [36] [37] [38] and there will likely be many more reports in the coming months. As mentioned above, these studies have the advantage over traditional candidate gene association studies in that they can identify novel genes and pathways, but also have the advantage over linkage studies in that they will identify genes with small effects. 32 In addition, because genomewide association studies require many hundreds of thousands of SNPs, this approach will localize the susceptibility locus to a much smaller region (5500 kb) than is typically possible in a linkage study and, in some cases, provide fine mapping markers at the same time. Although at present both the financial costs and computational demands limit its application, we predict that genome-wide association studies in large populations of cases and controls will become standard approaches to gene discovery over the next decade, just as genome-wide microsatellite typing in families with asthma and other complex traits went from a daunting endeavor in 1996 to an automated and affordable application in just a few years.
A review of the literature
We previously reviewed the results of association studies with asthma and atopy phenotypes that were published through mid-2003. 39 In that review, we included all genes that had at least one positive association with an asthma or atopy phenotype and summarized the results of all studies of these genes. We identified the genes by searching the public databases using the keywords 'association' or 'case-control' together with each of the following terms: 'asthma', 'bronchial hyperresponsiveness', 'BHR', 'atopy', 'SPT', 'atopic dermatitis', 'IgE', or 'drug response'. This identified a group of genes with at least one significant association reported and we then searched for all other studies of those genes.
Here, we updated this review nearly through 2005, and include all genes that were identified as a potential susceptibility locus in either association or positional cloning studies. The same caveats and limitations discussed in our earlier review apply to this analysis. For example, we consider the gene as the unit of replication and do not differentiate between the different asthma-and atopy-related phenotypes with respect to replication and nonreplication (both discussed below in more detail). We acknowledge that there are inherent biases in such literature reviews in that negative studies are less likely to be published. Moreover, if the first published study yields a negative result, it is less likely that other investigators will study that gene. However, because even the most replicated genes have one or more negative studies, a gene with an initial negative result could still be a true susceptibility gene in other populations or with respect to other phenotypes or other variants than those studied in the initial report. As a result, we classify genes largely based on the number of positive reports because there are likely many negative studies for all of the genes shown in Figure 1 that have not been published. Lastly, we did not take into account the size of the study samples, whether the genotype data were in Hardy-Weinberg proportions, the effect size, or the overall quality of the analysis, but report positive findings when the investigators interpreted their results to support an association and negative findings when the investigators interpret their results as lack of an association.
The gene as the unit of replication
Although replication of association results remains the gold standard, a recent review has suggested that the gene, rather than specific variants or haplotypes, should be considered the unit of replication. 40 Whereas genes are consistent with respect to position, sequence, and function in all human populations, this is not necessarily the case for any specific SNP or haplotype. Neale and Sham 40 propose that all common variation within a gene should be considered jointly in association studies, an approach that is now practical with the recent completion the International HapMap Project. 41 We have taken liberty with this recommendation for the purpose of our review, and consider an association with any variant or combination of variants within the same gene to represent a replication, regardless of whether the association is with the same variation as that reported in the initial study. We believe that this is a useful operational definition because there are now many examples of established associations with different functional variants within the same gene or with opposite alleles at the same SNP in different populations. For example, a functional promoter SNP in the IL13 gene 42 is associated with asthma or atopic phenotypes in some populations (Table S1) , whereas a functional coding SNP 43 in the IL13 gene is associated with asthma or atopic phenotypes in other populations (Table S1 ), the particular allele at a functional promoter SNP in the CD14 gene 44 that is associated with atopy varies depending on exposure to levels of environmental endotoxin, 28 and the specific variants and haplotypes in the ADAM33 gene that are associated with asthma phenotypes differ among studies (Table S1 ). We believe that the overall evidence for each of these three genes being true susceptibility loci is compelling, yet the nature of the associations indicates that susceptibility is complex and that there may not be one susceptibility variant or haplotype in these genes in all populations. The specific associations that are reported in any particular population are influenced to varying degrees by the phenotypes measured in the study sample, how the sample was ascertained, population-specific allele frequencies and patterns of LD, and environmental exposures that might differ between study samples. As it is likely that many other susceptibility loci will have equally complex patterns of association, we used this inclusive criterion for determining replications.
The phenotype: asthma, atopy, and related phenotypes Although it is likely that the underlying genetic architecture of the clinical conditions of asthma, allergic rhinitis (AR), and atopic dermatitis (AD) differs, it is clear that many common genes and pathways also contribute to the onset, course, or severity of these related diseases. Likewise, many phenotypes associated with these conditions, such as bronchial hyperresponsiveness (BHR), measures of lung function, and total and specific IgE, are influenced by the same genes. For example, the functional À589C/T promoter polymorphism in the IL4 gene 45 has been specifically associated with asthma, AD, AR, total serum IgE, specific IgE to house dust mites (HDM), or lung function measures, and the Gly237Glu amino-acid polymorphism in the FCER1B gene has been specifically associated with asthma, BHR, total serum IgE, and specific IgE in different populations around the world (Table S1 ). The specific associations that are reported in any particular population are influenced by the same factors described above, but the specific phenotypes measured and ascertainment of the study sample probably have the most significant effects. As a result of the unevenness between studies with respect to both of these factors, we considered an association with any phenotype to represent a replication, as in our earlier review.
The top 100 asthma genes
In our previous review, we identified 64 genes that had at least one positive association study reported. 39 Among those genes, 33 were replicated in at least a second study and eight genes were replicated in five or more studies.
In the approximately 2 years since our last review, there are now 118 genes that have been associated with an asthma-or atopy-related phenotype, 54 genes that have been replicated in 2-5 independent samples, 15 genes in 6-10 independent samples, and 10 genes in 410 independent samples, reported in a total of 492 papers. These studies are described in Table S1 and summarized in Figure 1 . The most noticeable differences in the associations reported in the past 2 years compared with those reported earlier are that the recent studies more often include larger samples of cases and controls, consider multiple variants and haplotypes, and include gene-gene and gene-environment interactions. The larger sample sizes should, in principle, reduce both the type I and type II error rates, but considering multiple variants, haplotypes, and interactions can increase the type I error rate if multiple testing is not appropriately taken into account in the assessment of significance. These topics were discussed in more detail in our previous review. 39 The elite group of genes that have been associated with an asthma or atopy phenotype in 410 studies include seven of the eight genes highlighted in our previous review (IL4, IL13, ADRB2, TNF, HLA-DRB1, FCER1B, and IL4RA), as well as the CD14, HLA-DQB1, and ADAM33 genes. It is notable that the first positionally cloned asthma gene, ADAM33, 10 has now been associated with asthma or a related phenotype in 410 independent samples. Moreover, a recent meta-analysis combining the results of both positive and negative studies from eight populations yielded a maximum odds ratio of 1.46 (P ¼ 0.0001) for a common SNP in ADAM33, called ST þ 7 (risk allele frequency ¼ 84.9% in asthmatics and 79.1% in controls). 46 This effect size is less than that estimated in the original report, 10 a commonly observed phenomenon in genetic association studies. 47, 48 However, this estimate is probably within the range of what to expect for most asthma susceptibility alleles, particularly those with common frequencies.
An additional 15 genes have been associated with an asthma or atopy phenotype in 6-10 studies, including another positionally cloned gene, GRPA. 7 The largest group of genes was associated with an asthma or atopy phenotype in 2-5 independent samples (Figure 1 ). These include three positionally cloned genes, DPP10, 6 HLA-G, 8 and PFH11. 11 Finally, 39 genes have been associated with an asthma or allergy phenotype in just a single sample. This includes 24 genes for which only a single study has been published and 15 genes with one or more follow-up studies that failed to replicate the association. Among the former group is the most recently positionally cloned gene, CYFIP2.
9 Although the latter group of 15 genes failed to replicate in one or more studies, it might be premature to dismiss them all as type I errors in the initial report because in many cases the replication studies examined different variation in the same gene or different phenotypes from those in the initial study, or did not have sufficient power to exclude an association with any degree of confidence. Therefore, although most of these genes may not be true asthma or atopy susceptibility genes, we consider the jury to still be out on many of the genes in the latter two groups.
To summarize, we consider the 25 genes that have been associated with asthma-or atopy-related phenotypes in six or more independent samples to be true susceptibility genes. However, as we have pointed out previously, 15, 39 no one gene will be an 'asthma' gene in all populations. This likely reflects the complex etiology of these conditions, the modest effects of these genes on risk, and the important roles of gene-gene and geneenvironment interactions in determining susceptibility.
Concluding remarks and future directions
Asthma and atopy are remarkably heterogeneous phenotypes. Overall risk, age of onset, and severity are influenced by numerous biological pathways that interact with environmental exposures. It is not surprising, therefore, that the associated genes have diverse functions and act in multiple pathways. Although the number of genes that contribute to any one of these related phenotypes is still unknown, it is likely to be quite large. On the basis of this literature review, we suggest that the total number of genes that contribute to risk may exceed 100 and that the individual effect of any one of these genes on disease risk is quite small. However, it is also likely that for any particular phenotype there may be a fewer number of genes that account for most of the variation in risk. Moreover, an even smaller subset of genes may determine risk for any one person.
A great challenge, therefore, as we move forward is to identify constellations of genes that interact to determine risk for specific patients. Such studies should take into account environmental context, as much as possible, including easily measurable traits such as parent-oforigin, parental affection status, and sex. 8, 49, 50 These approaches will require very large sample sizes of carefully phenotyped patients, comprehensive genetic surveys of targeted genes or of genome-wide variation, and rigorous statistical approaches that account for multiple comparisons. Complementary approaches may also be required to fully characterize the underlying architecture. For example, expression profiling in human tissues and animal models 51, 52 can identify interacting sets of genes that could serve as candidates or provide quantitative phenotypes (eQTLs) 53 for genetic studies; bioinformatic 54 or systems-based approaches 55 can identify disease-related variants that interact in molecular or biochemical pathways; and functional analyses of associated variants or haplotypes can provide clues to pathogenesis. 43, 56 Such 'molecular phenotyping' of patients with asthma or atopic diseases may inform decisions regarding treatment, and thereby laying the foundation for genomic medicine in the next decade.
